Antibacterial use of halogenated salicylanilides
The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus , in particular Staphylococcus aureus , and Streptococcus , in particular Streptococcus pyogenes . Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.
1. A method of treating pyoderma in a non-human animal, the method comprising topically administering to said non-human animal an effective amount of oxyclozanide.
2. The method of claim 1 , wherein the animal is a companion animal.
3. The method of claim 1 , wherein the animal is a dog or cat.
4. The method of claim the method of claim 1 , wherein the pyoderma is caused by Staphylococcus spp.
5. The method of claim the method of claim 1 , wherein the pyoderma is caused by Staphylococcus aureus.
6. The method of claim 1 , wherein the non-human animal is a dog.
7. The method of claim 1 , wherein the oxyclozanide is topically administered to said non-human animal in the form of a pharmaceutical composition comprising from 1% to 20% by weight oxyclozanide.
8. The method of claim 1 , wherein the oxyclozanide is topically administered to said non-human animal in the form of a pharmaceutical composition comprising from 2% to 20% by weight oxyclozanide.
9. The method of claim 1 , wherein the oxyclozanide is topically administered to said non-human animal in the form of a pharmaceutical composition comprising from 2% to 10% by weight oxyclozanide.
10. The method of claim 1 , wherein the oxyclozanide is topically administered to said non-human animal in the form of an epicutaneous pharmaceutical composition.
11. The method of claim 1 , wherein the oxyclozanide is topically administered to said non-human animal in the form of a pharmaceutical composition selected from a cream, a foam, a gel, droplets, a lotion and an ointment.
12. The method of claim 1 , wherein the oxyclozanide is topically administered to said non-human animal once per day.
13. A method of treating pyoderma in a dog, the method comprising topically administering to said dog an effective amount of oxyclozanide.
14. The method of claim 13 , wherein the pyoderma is caused by Staphylococcus spp.
15. The method of claim 13 , wherein the pyoderma is caused by Staphylococcus aureus.
16. The method of claim 13 , wherein the oxyclozanide is topically administered to said dog in the form of a pharmaceutical composition comprising from 1% to 20% by weight oxyclozanide.
17. The method of claim 13 , wherein the oxyclozanide is topically administered to said dog in the form of a pharmaceutical composition comprising from 2% to 20% by weight oxyclozanide.
18. The method of claim 13 , wherein the oxyclozanide is topically administered to said dog in the form of a pharmaceutical composition comprising from 2% to 10% by weight oxyclozanide.
19. The method of claim 13 , wherein the oxyclozanide is topically administered to said dog in the form of an epicutaneous pharmaceutical composition.
20. The method of claim 13 , wherein the oxyclozanide is topically administered to said dog in the form of a pharmaceutical composition selected from a cream, a foam, a gel, droplets, a lotion and an ointment.
21. The method of claim 13 , wherein the oxyclozanide is topically administered to said dog once per day.